NCT06610643View on ClinicalTrials.gov

Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 21, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions

COVID-19SARS-CoV-2Immunocompromised

Interventions

DRUG

combination therapy

A combination of 5-day remdesivir and 10-day Nirmatrelvir/Ritonavir

DRUG

SOC

Standard of care

Trial Locations (1)

100225

National Taiwan University Hospital, Taipei

All Listed Sponsors

lead

National Taiwan University Hospital

OTHER

NCT06610643 - Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients | Biotech Hunter | Biotech Hunter